SuperworthApnimed APMD
- Market cap
- $790.6M
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- not a meaningful number
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Charts
Financials
| Income statement | Q1 FY25 | Q2 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|
| $3.1M | $17.1M | $84.8M | $12.1M | |
| R&D | $23.5M | $16M | $8.1M | $9.9M |
| SG&A | $5.5M | $5.4M | $6.5M | $12.7M |
| −$27.1M | −$5.9M | $68M | −$11.7M | |
| Pre-tax income | −$26.7M | −$5.6M | $70.4M | $126.1M |
| $0 | $0 | $0 | $0 | |
| Net income | −$28.6M | −$69.5M | $67.7M | $125.9M |
| −$6.03 | −$14.61 | $2.12 | $3.89 | |
| 4.7M | 4.8M | 32M | 32.4M |
Revenue: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.
R&D: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.
SG&A: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.
Operating income: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.
Income tax: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.
Net income: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.
EPS, diluted: 4 periods, Q1 FY25 to Q2 FY26: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY25 and Q1 FY26: share-days: the 6-month average less the second quarter's.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Apnimed's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| APMDApnimed | $790.6M | n/m | n/a | n/m | n/m | n/m | |
| ABUSArbutus Biopharma | $831M | 5.4× | 5.6× | 4.6× | n/m | 84.2% | |
| COLLCollegium Pharmaceutical | $747.5M | 18.5× | 19.1× | 0.9× | +14% | 5.9% | |
| CRMDCorMedix | $611.9M | 3.7× | 4.0× | 1.3× | +281% | 40.5% | |
| AMPHAmphastar Pharmaceuticals | $1.1B | 14.8× | 20.6× | 1.5× | +1% | 10.8% | |
| ZVRAZevra Therapeutics | $582.6M | 10.5× | 12.3× | 4.3× | +119% | 42.8% | |
| IRWDIronwood Pharmaceuticals | $571.7M | 4.5× | 14.9× | 1.5× | +26% | 33.4% | |
| PBYIPuma Biotechnology | $568.9M | 21.2× | 12.3× | 2.5× | −3% | 11.6% | |
| OMEROmeros | $1.2B | 10.9× | 11.7× | n/m | n/m | n/m | |
| ARVNArvinas | $477.3M | 45.6× | 52.3× | 1.5× | −15% | 2.9% | |
| PCRXPacira BioSciences | $1.5B | 104× | 65.6× | 1.9× | +6% | 2.0% | |
| Peer median | $679.7M | 12.8× | 13.6× | 1.5× | +10% | 11.6% |
More on Apnimed
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .